Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionWellington Management Group Llp
Latest Disclosed Ownership12,384,194 shares
Ownership 4.90%
Wellington Management Group Llp ownership in VRTX / Vertex Pharmaceuticals Incorporated

2018-02-08 - Wellington Management Group Llp has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 12,384,194 shares of Vertex Pharmaceuticals Incorporated (US:VRTX). This represents 4.9 percent ownership of the company. In their previous filing dated 2017-02-09 , Wellington Management Group Llp had reported owning 14,920,158 shares, indicating a decrease of -17.00 percent.

Wellington Management Group Llp has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2018-02-08 2018-02-08 13G/A 14,920,158 12,384,194 -17.00 4.90 -18.60
2017-02-09 2017-02-09 13G/A 14,863,986 14,920,158 0.38 6.02 -0.50
2016-02-11 2016-02-11 13G/A 14,863,986 6.05
2015-02-12 2015-02-12 13G/A 17,194,032 7.15
2014-02-14 2014-02-14 13G 16,541,986 7.08
2012-02-14 2012-02-14 13G/A 4,216,082 2.02

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,212,589 -609,142 -15.94 1,434,549 -17.20 0.0380
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,821,731 -950,311 -19.91 1,732,620 -7.29 0.3036
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,772,042 -41,344 -0.86 1,868,923 -12.79 0.3271
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,813,386 -641,362 -11.76 2,142,919 -18.97 0.3889
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,454,748 -461,336 -7.80 2,644,571 11.00 0.5087
2025-02-12 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,916,084 1,117,214 23.28 2,382,407 6.75 0.4363
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,798,870 704,421 17.20 2,231,858 16.29 0.3909
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,094,449 -463,784 -10.17 1,919,150 0.72 0.3426
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,558,233 -670,305 -12.82 1,905,387 -10.44 0.3376
2024-02-12 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,228,538 -1,297,313 -19.88 2,127,440 -6.25 0.3971
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,525,851 -1,027,043 -13.60 2,269,299 -14.62 0.4551
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,552,894 35,346 0.47 2,657,939 12.22 0.5039
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,517,548 689,965 10.11 2,368,554 20.13 0.4694
2023-02-13 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,827,583 -1,201,759 -14.97 1,971,669 -15.19 0.3954
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,029,342 -206,297 -2.50 2,324,815 0.18 0.4952
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,235,639 181,929 2.26 2,320,720 10.42 0.4674
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,053,710 1,535,255 23.55 2,101,776 46.83 0.3599
2022-02-11 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,518,455 427,366 7.02 1,431,454 29.56 0.2289
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,091,089 -2,204,600 -26.58 1,104,862 -33.95 0.1879
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,295,689 209,325 2.59 1,672,660 -3.74 0.2784
2021-05-17 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,086,364 -1,120,147 -12.17 1,737,680 -20.14 0.3060
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,206,511 3,020,047 48.82 2,175,867 29.25 0.4007
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,186,464 -275,346 -4.26 1,683,460 -10.26 0.3485
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,461,810 -1,149,958 -15.11 1,875,927 3.57 0.4177
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,611,768 175,609 2.36 1,811,221 11.24 0.4793
2020-02-11 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,436,159 -807,388 -9.79 1,628,147 16.58 0.3412
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,243,547 -15,065 -0.18 1,396,624 -7.78 0.3149
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,258,612 -570,173 -6.46 1,514,465 -6.75 0.3353
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,828,785 210,383 2.44 1,624,056 13.72 0.3678
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,618,402 -887,386 -9.34 1,428,156 -22.05 0.3575
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,505,788 -802,611 -7.79 1,832,144 4.57 0.3858
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,308,399 -767,106 -6.93 1,752,014 -2.94 0.3900
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,075,505 -1,308,689 -10.57 1,805,086 -2.74 0.4085
2018-02-13 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,384,194 -883,152 -6.66 1,855,897 -7.99 0.4101
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,267,346 -2,600,854 -16.39 2,017,168 -1.36 0.4630
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,868,200 -1,897,733 -10.68 2,044,935 5.26 0.4815
2017-05-11 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,765,933 2,845,775 19.07 1,942,704 76.74 0.4679
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,920,158 496,319 3.44 1,099,167 -12.62 0.2757
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,423,839 336,192 2.39 1,257,901 3.80 0.3151
2016-08-15 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,087,647 -639,526 -4.34 1,211,820 3.52 0.3132
2016-05-13 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,727,173 -136,813 -0.92 1,170,662 -37.41 0.3081
2016-02-12 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,863,986 1,405,220 10.44 1,870,336 33.44 0.4893
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,458,766 -416,455 -3.00 1,401,597 -18.19 0.3908
2015-08-14 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,875,221 -1,483,538 -9.66 1,713,311 -5.44 0.4420
2015-05-15 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,358,759 -1,835,273 -10.67 1,811,873 -11.30 0.4658
2015-02-13 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,194,032 -2,664,428 -13.42 2,042,651 -8.41 0.5400
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,858,460 3,397,356 20.64 2,230,304 43.10 0.6145
2014-08-14 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,461,104 178,644 1.10 1,558,537 35.35 0.4192
2014-05-15 2014-03-31 13F VERTEX COM 92532F100 16,282,460 -259,526 -1.57 1,151,495 -6.31 0.3196
2014-02-14 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,541,986 4,439,553 36.68 1,229,070 33.94 0.3534
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,102,433 -1,241,549 -9.30 917,607 -13.90 0.2873
2013-08-14 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,343,982 13,343,982 1,065,783 0.3478
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-05-11 2017-03-31 13F VERTEX PHARMACEUTICALS COM Call 100 280 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.